Analyst Price Target is $31.00
▲ +282.24% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for 89bio in the last 3 months. The average price target is $31.00, with a high forecast of $53.00 and a low forecast of $12.00. The average price target represents a 282.24% upside from the last price of $8.11.
Current Consensus is
Moderate Buy
The current consensus among 7 contributing investment analysts is to moderate buy stock in 89bio. This Moderate Buy consensus rating has held steady for over two years.
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.
Read More